Viatris (XSWX:VTRS) Accounts Payable: CHF945 Mil (As of Mar. 2026)


XSWX:VTRS Viatris Inc XSWX:VTRS
60 GF Score
Price CHF13.06
GF Value CHF8.89
! 8 Warning Signs
View Full Analysis

What is Viatris Accounts Payable?

Viatris XSWX:VTRS +0.62% 60 Accounts Payable is CHF945 Mil as of Mar. 2026. GuruFocus rates XSWX:VTRS with a GF Score™ of 60/100 and a GF Value™ of CHF8.89. The stock has 8 warning signs investors should review.

Viatris's Accounts Payable for the quarter that ended in Mar. 2026 was CHF945 Mil.

Viatris's quarterly Accounts Payable declined from Sep. 2025 (CHF1,056 Mil) to Dec. 2025 (CHF1,031 Mil) and declined from Dec. 2025 (CHF1,031 Mil) to Mar. 2026 (CHF945 Mil).

Viatris's annual Accounts Payable increased from Dec. 2023 (CHF1,195 Mil) to Dec. 2024 (CHF1,208 Mil) but then declined from Dec. 2024 (CHF1,208 Mil) to Dec. 2025 (CHF1,031 Mil).

Viatris Accounts Payable Historical Data

* Premium members only.

The historical data trend for Viatris's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Viatris Accounts Payable Chart

Viatris Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 972.67 1,078.79 1,194.64 1,208.39 1,030.95

Viatris Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,341.48 1,073.42 1,055.95 1,030.95 944.60
XSWX:VTRS
60GF Score
Viatris Inc XSWX:VTRS
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Viatris Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of CHF945 Mil mean?
Viatris (XSWX:VTRS) has a Accounts Payable of CHF945 Mil as of Mar. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Viatris and its competitors.
Is Viatris' Accounts Payable too high?
Viatris' current Accounts Payable is CHF945 Mil. Overall, Viatris has a GF Score™ of 60/100, reflecting its overall financial health beyond just this single metric.
How does Viatris' Accounts Payable compare to NBIX and UTHR?
Viatris' Accounts Payable of CHF945 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Drug Manufacturers company?
A good Accounts Payable depends on the Drug Manufacturers industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Viatris and its competitors. Viatris's current Accounts Payable is CHF945 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viatris stock overvalued right now?
Viatris (XSWX:VTRS) has a current Accounts Payable of CHF945 Mil. The stock's GF Value™ is CHF8.89, compared to a current price of CHF13.06 — trading 46.9% above its estimated fair value. The current Accounts Payable is CHF945 Mil. Viatris' overall GF Score™ is 60/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Viatris (XSWX:VTRS), the current Accounts Payable is CHF945 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Viatris (XSWX:VTRS) Overvalued in 2026?

Based on GuruFocus' analysis, Viatris stock appears to be overvalued. The current stock price of CHF13.06 is trading 46.9% above its estimated GF Value™ of CHF8.89.

Key valuation signals for XSWX:VTRS:

  • Accounts Payable: CHF945 Mil
  • GF Value™: CHF8.89 vs. price of CHF13.06 (46.9% above fair value)
  • GF Score™: 60/100 with 8 warning signs

No single metric tells the full story. See the XSWX:VTRS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Viatris Business Description

Address 1000 Mylan Boulevard, Canonsburg, PA, USA, 15317
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
60GF Score

Get the complete analysis for XSWX:VTRS

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF13.06
Price
CHF8.89
GF Value